16,675,173 Shares in Sana Biotechnology, Inc. $SANA Acquired by BlackRock Inc.

Key Points

• BlackRock acquired 16.68 million Sana Biotechnology shares in the second quarter, valued at approximately $58.2 million, giving it a 5.99% stake. Institutional investors and hedge funds collectively own 88.23% of the company.
• Analyst sentiment is generally positive but mixed: Sana has a consensus rating of “Moderate Buy” and an average price target of $9.33, despite some recent downgrades and a reduced Bank of America target.
• Sana shares opened at $3.87, with a 52-week range of $2.61 to $6.55. The clinical-stage biotech recently reported a quarterly loss of $0.13 per share, beating estimates for a $0.15 loss.

BlackRock Inc. bought a new position in Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 16,675,173 shares of the company's stock, valued at approximately $58,196,000. BlackRock Inc. owned 5.99% of Sana Biotechnology as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Walleye Capital LLC purchased a new position in Sana Biotechnology during the 2nd quarter valued at about $35,000. Royal Bank of Canada boosted its holdings in shares of Sana Biotechnology by 76.8% during the first quarter. Royal Bank of Canada now owns 12,285 shares of the company's stock worth $35,000 after purchasing an additional 5,338 shares during the period. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Sana Biotechnology during the third quarter worth approximately $36,000. Rockefeller Capital Management L.P. grew its position in Sana Biotechnology by 74.3% during the fourth quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company's stock valued at $39,000 after purchasing an additional 4,088 shares in the last quarter. Finally, Russell Investments Group Ltd. purchased a new position in Sana Biotechnology during the third quarter valued at approximately $39,000. 88.23% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently commented on SANA. Weiss Ratings upgraded shares of Sana Biotechnology from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, July 23rd. Bank of America reduced their price objective on Sana Biotechnology from $7.00 to $6.00 and set a "buy" rating for the company in a research report on Friday, August 14th. Rodman & Renshaw initiated coverage on Sana Biotechnology in a research note on Monday, May 11th. They issued a "buy" rating and a $16.00 target price on the stock. TD Cowen raised Sana Biotechnology to a "strong-buy" rating in a research report on Monday, August 24th. Finally, Wall Street Zen downgraded Sana Biotechnology from a "hold" rating to a "sell" rating in a research note on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $9.33.

Sana Biotechnology Price Performance

NASDAQ SANA opened at $3.87 on Tuesday. Sana Biotechnology, Inc. has a 52-week low of $2.61 and a 52-week high of $6.55. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of -5.09 and a beta of 2.16. The company's fifty day moving average is $3.58 and its two-hundred day moving average is $3.41.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.02. As a group, sell-side analysts expect that Sana Biotechnology, Inc. will post -0.72 earnings per share for the current fiscal year.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company's core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source